The biomarkers consist of a variety of cells and cell clusters that originated from the tumor site. The CAMLs are the most common tumor associated cells found in the blood of cancer patients. 

The drug target under consideration can be validated by identifying and staining the target in CAMLs.

CAMLs deliver high quality DNA for sequencing for tumor mutations, amplifications, deletions and methylations.

For clinical trial recruitment, CAML size is an indication of aggressiveness of the patient’s cancer.  There are a variety of features of the cancer associated cells that can determine the prognosis of the patient’s cancer.

Companion diagnostics can be easily developed.  This is useful for identifying patients for clinical trials, and for therapy after FDA approval.

The treatment response of the therapy can usually be determined by the LifeTracDx assay as early as 30 days after the first dose. 

The expression of the drug target on the tumor can change over time during therapy. It is important to have this information. The ability to continually monitor treatment response is important.

Contact us for

• Clinical trials

• Partnering

• Licensing